Epigenetics Market By Product (Kits, Reagents, Enzymes, Instruments), By Application (Oncology, Non Oncology), By End User (Academic and Research Institutes, Pharmaceutical and Biotechnology Companies, Contract Research Organizations): Global Opportunity Analysis and Industry Forecast, 2020-2030
The global epigenetics market was valued at $1,018.1 million in 2020, and is projected to reach $4,056.86 million by 2030, registering a CAGR of 14.8% from 2021 to 2030.
Epigenetics is a stream of genetics that involves study of cellular and physiological trait variations initiated by external or ecological aspects, which turn genes on and off and affect cellular ability to read genes without being affected by changes in genotype. Epigenetics itself means in addition to alterations in genomic sequence, which means it results into changes in an organism’s phenotype rather than genotype, wherein the underlying DNA or RNA sequence remains unchanged. Epigenetic alterations are essential for development as they are dynamic and change with respect to environmental stimuli. However, these changes can be stable and could be passed from one generation to another. Biology and genetic expressions of most organisms are affected by epigenetics, which makes it one of the most crucial fields of developmental genetics and molecular biology. Methylation, acetylation, phosphorylation, ubiquitylation, and sumolyation are some of the epigenetic mechanisms that have been discovered.
The epigenetics market is expected to grow significantly during the forecast period, owing to rise in incidences of cancer and surge in its application in other chronic diseases such as cardiovascular disorders, metabolic diseases, infectious diseases, and inflammatory diseases. Increase in R&D activities, surge in investments in R&D, growth in epigenetic applications for non-oncology diseases, and increase in partnership between academic, pharmaceutical, and biotechnology companies significantly drive the market growth. However, high cost of instruments and lack of trained professionals impede the market growth.
Furthermore, untapped potential of emerging markets provides lucrative opportunities to the market players. Moreover, rise in application of epigenetics processes underlying illness onset and progression has proven critical in recent years for creation of innovative early diagnostic and prognosis biomarkers for assessing patients and its utilization in precision medicine.
The epigenetics market is segmented on the basis of product, application, end user, and region. By product, it is divided into enzymes, kits, instruments, and reagents. The enzymes segment is further divided into DNA ligases, DNA polymerases, other DNA-modifying enzymes, acetylases, methyltransferases, other protein-modifying enzymes, reverse transcriptase, RNA ligases, and other RNA-modifying enzymes. The kits segment is further subdivided into ChIP sequencing kits, bisulfite conversion kits, whole genome amplification kits, 5-hmC & 5-mC analysis kits, and RNA sequencing kits, and others. The instrument segment is further categorized into mass spectrometers, next-generation sequencers, qPCRs, sonicators, and others. The reagents segment is further divided into antibodies, buffers, histones, magnetic beads, primers, and others.
On the basis of application, the market is segmented into oncology and non-oncology. The oncology segment is further sub segmented into solid tumors and liquid tumors. Non-oncology applications include metabolic diseases, infectious diseases, inflammatory diseases, cardiovascular diseases, and other applications. By end user, it is segmented into academic & government research institutes, pharmaceutical & biotechnology companies, and contract research organizations (CROs). By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Major players profiled in the report are Abcam Plc., Active Motif, Inc., Agilent Technologies, Inc., Hologic Inc. (Diagenode), Illumina Inc., Merck KGaA (Merck Millipore), PerkinElmer, Inc., QIAGEN N.V., Thermo Fisher Scientific Inc., and Zymo Research.
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the epigenetics market analysis from 2020 to 2030 to identify the prevailing epigenetics market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the epigenetics market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global epigenetics market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Product
Reagents
Enzymes
Instruments
Kits
By Application
Oncology
Non Oncology
By End User
Academic and Research Institutes
Pharmaceutical and Biotechnology Companies
Contrac Research Organizations
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia-Pacific
LAMEA
Middle East And Africa
Latin America
Key Market Players
Abcam Plc.
Active Motif, Inc.
Agilent Technologies, Inc.
Hologic Inc.
Illumina Inc.
Merck Millipore
PerkinElmer, Inc.
QIAGEN N.V.
Thermo Fisher Scientific Inc.
Zymo Research
- CHAPTER 1:INTRODUCTION
- 1.1.Report description
- 1.2.Key market segments
- 1.3.Key benefits to the stakeholders
- 1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models
- CHAPTER 2:EXECUTIVE SUMMARY
- 2.1.Key findings of the study
- 2.2.CXO Perspective
- CHAPTER 3:MARKET OVERVIEW
- 3.1.Market definition and scope
- 3.2.Key findings
- 3.2.1.Top investment pockets
- 3.3.Porter’s five forces analysis
- 3.4.Top player positioning
- 3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
- 3.6.COVID-19 Impact Analysis on the market
- CHAPTER 4: EPIGENETICS MARKET, BY PRODUCT
- 4.1 Overview
- 4.1.1 Market size and forecast
- 4.2 Kits
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market analysis by country
- 4.3 Reagents
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market analysis by country
- 4.4 Enzymes
- 4.4.1 Key market trends, growth factors and opportunities
- 4.4.2 Market size and forecast, by region
- 4.4.3 Market analysis by country
- 4.5 Instruments
- 4.5.1 Key market trends, growth factors and opportunities
- 4.5.2 Market size and forecast, by region
- 4.5.3 Market analysis by country
- CHAPTER 5: EPIGENETICS MARKET, BY APPLICATION
- 5.1 Overview
- 5.1.1 Market size and forecast
- 5.2 Oncology
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market analysis by country
- 5.3 Non Oncology
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market analysis by country
- CHAPTER 6: EPIGENETICS MARKET, BY END USER
- 6.1 Overview
- 6.1.1 Market size and forecast
- 6.2 Academic and Research Institutes
- 6.2.1 Key market trends, growth factors and opportunities
- 6.2.2 Market size and forecast, by region
- 6.2.3 Market analysis by country
- 6.3 Pharmaceutical and Biotechnology Companies
- 6.3.1 Key market trends, growth factors and opportunities
- 6.3.2 Market size and forecast, by region
- 6.3.3 Market analysis by country
- 6.4 Contract Research Organizations
- 6.4.1 Key market trends, growth factors and opportunities
- 6.4.2 Market size and forecast, by region
- 6.4.3 Market analysis by country
- CHAPTER 7: EPIGENETICS MARKET, BY REGION
- 7.1 Overview
- 7.1.1 Market size and forecast
- 7.2 North America
- 7.2.1 Key trends and opportunities
- 7.2.2 North America Market size and forecast, by Product
- 7.2.3 North America Market size and forecast, by Application
- 7.2.4 North America Market size and forecast, by End User
- 7.2.5 North America Market size and forecast, by country
- 7.2.5.1 U.S.
- 7.2.5.1.1 Market size and forecast, by Product
- 7.2.5.1.2 Market size and forecast, by Application
- 7.2.5.1.3 Market size and forecast, by End User
- 7.2.5.2 Canada
- 7.2.5.2.1 Market size and forecast, by Product
- 7.2.5.2.2 Market size and forecast, by Application
- 7.2.5.2.3 Market size and forecast, by End User
- 7.2.5.3 Mexico
- 7.2.5.3.1 Market size and forecast, by Product
- 7.2.5.3.2 Market size and forecast, by Application
- 7.2.5.3.3 Market size and forecast, by End User
- 7.3 Europe
- 7.3.1 Key trends and opportunities
- 7.3.2 Europe Market size and forecast, by Product
- 7.3.3 Europe Market size and forecast, by Application
- 7.3.4 Europe Market size and forecast, by End User
- 7.3.5 Europe Market size and forecast, by country
- 7.3.5.1 Germany
- 7.3.5.1.1 Market size and forecast, by Product
- 7.3.5.1.2 Market size and forecast, by Application
- 7.3.5.1.3 Market size and forecast, by End User
- 7.3.5.2 France
- 7.3.5.2.1 Market size and forecast, by Product
- 7.3.5.2.2 Market size and forecast, by Application
- 7.3.5.2.3 Market size and forecast, by End User
- 7.3.5.3 U.K.
- 7.3.5.3.1 Market size and forecast, by Product
- 7.3.5.3.2 Market size and forecast, by Application
- 7.3.5.3.3 Market size and forecast, by End User
- 7.3.5.4 Italy
- 7.3.5.4.1 Market size and forecast, by Product
- 7.3.5.4.2 Market size and forecast, by Application
- 7.3.5.4.3 Market size and forecast, by End User
- 7.3.5.5 Spain
- 7.3.5.5.1 Market size and forecast, by Product
- 7.3.5.5.2 Market size and forecast, by Application
- 7.3.5.5.3 Market size and forecast, by End User
- 7.3.5.6 Rest of Europe
- 7.3.5.6.1 Market size and forecast, by Product
- 7.3.5.6.2 Market size and forecast, by Application
- 7.3.5.6.3 Market size and forecast, by End User
- 7.4 Asia-Pacific
- 7.4.1 Key trends and opportunities
- 7.4.2 Asia-Pacific Market size and forecast, by Product
- 7.4.3 Asia-Pacific Market size and forecast, by Application
- 7.4.4 Asia-Pacific Market size and forecast, by End User
- 7.4.5 Asia-Pacific Market size and forecast, by country
- 7.4.5.1 Japan
- 7.4.5.1.1 Market size and forecast, by Product
- 7.4.5.1.2 Market size and forecast, by Application
- 7.4.5.1.3 Market size and forecast, by End User
- 7.4.5.2 China
- 7.4.5.2.1 Market size and forecast, by Product
- 7.4.5.2.2 Market size and forecast, by Application
- 7.4.5.2.3 Market size and forecast, by End User
- 7.4.5.3 Australia
- 7.4.5.3.1 Market size and forecast, by Product
- 7.4.5.3.2 Market size and forecast, by Application
- 7.4.5.3.3 Market size and forecast, by End User
- 7.4.5.4 India
- 7.4.5.4.1 Market size and forecast, by Product
- 7.4.5.4.2 Market size and forecast, by Application
- 7.4.5.4.3 Market size and forecast, by End User
- 7.4.5.5 South Korea
- 7.4.5.5.1 Market size and forecast, by Product
- 7.4.5.5.2 Market size and forecast, by Application
- 7.4.5.5.3 Market size and forecast, by End User
- 7.4.5.6 Rest of Asia-Pacific
- 7.4.5.6.1 Market size and forecast, by Product
- 7.4.5.6.2 Market size and forecast, by Application
- 7.4.5.6.3 Market size and forecast, by End User
- 7.5 LAMEA
- 7.5.1 Key trends and opportunities
- 7.5.2 LAMEA Market size and forecast, by Product
- 7.5.3 LAMEA Market size and forecast, by Application
- 7.5.4 LAMEA Market size and forecast, by End User
- 7.5.5 LAMEA Market size and forecast, by country
- 7.5.5.1 Middle East And Africa
- 7.5.5.1.1 Market size and forecast, by Product
- 7.5.5.1.2 Market size and forecast, by Application
- 7.5.5.1.3 Market size and forecast, by End User
- 7.5.5.2 Latin America
- 7.5.5.2.1 Market size and forecast, by Product
- 7.5.5.2.2 Market size and forecast, by Application
- 7.5.5.2.3 Market size and forecast, by End User
- CHAPTER 8: COMPANY LANDSCAPE
- 8.1. Introduction
- 8.2. Top winning strategies
- 8.3. Product Mapping of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Key developments
- CHAPTER 9: COMPANY PROFILES
- 9.1 Abcam Plc.
- 9.1.1 Company overview
- 9.1.2 Company snapshot
- 9.1.3 Operating business segments
- 9.1.4 Product portfolio
- 9.1.5 Business performance
- 9.1.6 Key strategic moves and developments
- 9.2 Active Motif, Inc.
- 9.2.1 Company overview
- 9.2.2 Company snapshot
- 9.2.3 Operating business segments
- 9.2.4 Product portfolio
- 9.2.5 Business performance
- 9.2.6 Key strategic moves and developments
- 9.3 Agilent Technologies, Inc.
- 9.3.1 Company overview
- 9.3.2 Company snapshot
- 9.3.3 Operating business segments
- 9.3.4 Product portfolio
- 9.3.5 Business performance
- 9.3.6 Key strategic moves and developments
- 9.4 Hologic Inc.
- 9.4.1 Company overview
- 9.4.2 Company snapshot
- 9.4.3 Operating business segments
- 9.4.4 Product portfolio
- 9.4.5 Business performance
- 9.4.6 Key strategic moves and developments
- 9.5 Illumina Inc.
- 9.5.1 Company overview
- 9.5.2 Company snapshot
- 9.5.3 Operating business segments
- 9.5.4 Product portfolio
- 9.5.5 Business performance
- 9.5.6 Key strategic moves and developments
- 9.6 Merck Millipore
- 9.6.1 Company overview
- 9.6.2 Company snapshot
- 9.6.3 Operating business segments
- 9.6.4 Product portfolio
- 9.6.5 Business performance
- 9.6.6 Key strategic moves and developments
- 9.7 PerkinElmer, Inc.
- 9.7.1 Company overview
- 9.7.2 Company snapshot
- 9.7.3 Operating business segments
- 9.7.4 Product portfolio
- 9.7.5 Business performance
- 9.7.6 Key strategic moves and developments
- 9.8 QIAGEN N.V.
- 9.8.1 Company overview
- 9.8.2 Company snapshot
- 9.8.3 Operating business segments
- 9.8.4 Product portfolio
- 9.8.5 Business performance
- 9.8.6 Key strategic moves and developments
- 9.9 Thermo Fisher Scientific Inc.
- 9.9.1 Company overview
- 9.9.2 Company snapshot
- 9.9.3 Operating business segments
- 9.9.4 Product portfolio
- 9.9.5 Business performance
- 9.9.6 Key strategic moves and developments
- 9.10 Zymo Research
- 9.10.1 Company overview
- 9.10.2 Company snapshot
- 9.10.3 Operating business segments
- 9.10.4 Product portfolio
- 9.10.5 Business performance
- 9.10.6 Key strategic moves and developments
- LIST OF TABLES
- TABLE 1. GLOBAL EPIGENETICS MARKET, BY PRODUCT, 2020-2030,($MILLION)
- TABLE 2. EPIGENETICS MARKET REVENUE, FOR KITS, BY REGION , 2020-2030,($MILLION)
- TABLE 3. EPIGENETICS MARKET KITS BY COUNTRY, 2020-2030,($MILLION)
- TABLE 4. EPIGENETICS MARKET REVENUE, FOR REAGENTS, BY REGION , 2020-2030,($MILLION)
- TABLE 5. EPIGENETICS MARKET REAGENTS BY COUNTRY, 2020-2030,($MILLION)
- TABLE 6. EPIGENETICS MARKET REVENUE, FOR ENZYMES, BY REGION , 2020-2030,($MILLION)
- TABLE 7. EPIGENETICS MARKET ENZYMES BY COUNTRY, 2020-2030,($MILLION)
- TABLE 8. EPIGENETICS MARKET REVENUE, FOR INSTRUMENTS, BY REGION , 2020-2030,($MILLION)
- TABLE 9. EPIGENETICS MARKET INSTRUMENTS BY COUNTRY, 2020-2030,($MILLION)
- TABLE 10. GLOBAL EPIGENETICS MARKET, BY APPLICATION, 2020-2030,($MILLION)
- TABLE 11. EPIGENETICS MARKET REVENUE, FOR ONCOLOGY, BY REGION , 2020-2030,($MILLION)
- TABLE 12. EPIGENETICS MARKET ONCOLOGY BY COUNTRY, 2020-2030,($MILLION)
- TABLE 13. EPIGENETICS MARKET REVENUE, FOR NON ONCOLOGY, BY REGION , 2020-2030,($MILLION)
- TABLE 14. EPIGENETICS MARKET NON ONCOLOGY BY COUNTRY, 2020-2030,($MILLION)
- TABLE 15. GLOBAL EPIGENETICS MARKET, BY END USER, 2020-2030,($MILLION)
- TABLE 16. EPIGENETICS MARKET REVENUE, FOR ACADEMIC AND RESEARCH INSTITUTES, BY REGION , 2020-2030,($MILLION)
- TABLE 17. EPIGENETICS MARKET ACADEMIC AND RESEARCH INSTITUTES BY COUNTRY, 2020-2030,($MILLION)
- TABLE 18. EPIGENETICS MARKET REVENUE, FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION , 2020-2030,($MILLION)
- TABLE 19. EPIGENETICS MARKET PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES BY COUNTRY, 2020-2030,($MILLION)
- TABLE 20. EPIGENETICS MARKET REVENUE, FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION , 2020-2030,($MILLION)
- TABLE 21. EPIGENETICS MARKET CONTRACT RESEARCH ORGANIZATIONS BY COUNTRY, 2020-2030,($MILLION)
- TABLE 22. EPIGENETICS MARKET, BY REGION, 2020-2030,($MILLION)
- TABLE 23. NORTH AMERICA EPIGENETICS MARKET, BY PRODUCT, 2020-2030,($MILLION)
- TABLE 24. NORTH AMERICA EPIGENETICS MARKET, BY APPLICATION, 2020-2030,($MILLION)
- TABLE 25. NORTH AMERICA EPIGENETICS MARKET, BY END USER, 2020-2030,($MILLION)
- TABLE 26. NORTH AMERICA EPIGENETICS MARKET, BY COUNTRY, 2020-2030,($MILLION)
- TABLE 27. U.S. EPIGENETICS MARKET BY PRODUCT 2020-2030,($MILLION)
- TABLE 28. U.S. EPIGENETICS MARKET BY APPLICATION 2020-2030,($MILLION)
- TABLE 29. U.S. EPIGENETICS MARKET BY END USER 2020-2030,($MILLION)
- TABLE 30. CANADA EPIGENETICS MARKET BY PRODUCT 2020-2030,($MILLION)
- TABLE 31. CANADA EPIGENETICS MARKET BY APPLICATION 2020-2030,($MILLION)
- TABLE 32. CANADA EPIGENETICS MARKET BY END USER 2020-2030,($MILLION)
- TABLE 33. MEXICO EPIGENETICS MARKET BY PRODUCT 2020-2030,($MILLION)
- TABLE 34. MEXICO EPIGENETICS MARKET BY APPLICATION 2020-2030,($MILLION)
- TABLE 35. MEXICO EPIGENETICS MARKET BY END USER 2020-2030,($MILLION)
- TABLE 36. EUROPE EPIGENETICS MARKET, BY PRODUCT, 2020-2030,($MILLION)
- TABLE 37. EUROPE EPIGENETICS MARKET, BY APPLICATION, 2020-2030,($MILLION)
- TABLE 38. EUROPE EPIGENETICS MARKET, BY END USER, 2020-2030,($MILLION)
- TABLE 39. EUROPE EPIGENETICS MARKET, BY COUNTRY, 2020-2030,($MILLION)
- TABLE 40. GERMANY EPIGENETICS MARKET BY PRODUCT 2020-2030,($MILLION)
- TABLE 41. GERMANY EPIGENETICS MARKET BY APPLICATION 2020-2030,($MILLION)
- TABLE 42. GERMANY EPIGENETICS MARKET BY END USER 2020-2030,($MILLION)
- TABLE 43. FRANCE EPIGENETICS MARKET BY PRODUCT 2020-2030,($MILLION)
- TABLE 44. FRANCE EPIGENETICS MARKET BY APPLICATION 2020-2030,($MILLION)
- TABLE 45. FRANCE EPIGENETICS MARKET BY END USER 2020-2030,($MILLION)
- TABLE 46. U.K. EPIGENETICS MARKET BY PRODUCT 2020-2030,($MILLION)
- TABLE 47. U.K. EPIGENETICS MARKET BY APPLICATION 2020-2030,($MILLION)
- TABLE 48. U.K. EPIGENETICS MARKET BY END USER 2020-2030,($MILLION)
- TABLE 49. ITALY EPIGENETICS MARKET BY PRODUCT 2020-2030,($MILLION)
- TABLE 50. ITALY EPIGENETICS MARKET BY APPLICATION 2020-2030,($MILLION)
- TABLE 51. ITALY EPIGENETICS MARKET BY END USER 2020-2030,($MILLION)
- TABLE 52. SPAIN EPIGENETICS MARKET BY PRODUCT 2020-2030,($MILLION)
- TABLE 53. SPAIN EPIGENETICS MARKET BY APPLICATION 2020-2030,($MILLION)
- TABLE 54. SPAIN EPIGENETICS MARKET BY END USER 2020-2030,($MILLION)
- TABLE 55. REST OF EUROPE EPIGENETICS MARKET BY PRODUCT 2020-2030,($MILLION)
- TABLE 56. REST OF EUROPE EPIGENETICS MARKET BY APPLICATION 2020-2030,($MILLION)
- TABLE 57. REST OF EUROPE EPIGENETICS MARKET BY END USER 2020-2030,($MILLION)
- TABLE 58. ASIA-PACIFIC EPIGENETICS MARKET, BY PRODUCT, 2020-2030,($MILLION)
- TABLE 59. ASIA-PACIFIC EPIGENETICS MARKET, BY APPLICATION, 2020-2030,($MILLION)
- TABLE 60. ASIA-PACIFIC EPIGENETICS MARKET, BY END USER, 2020-2030,($MILLION)
- TABLE 61. ASIA-PACIFIC EPIGENETICS MARKET, BY COUNTRY, 2020-2030,($MILLION)
- TABLE 62. JAPAN EPIGENETICS MARKET BY PRODUCT 2020-2030,($MILLION)
- TABLE 63. JAPAN EPIGENETICS MARKET BY APPLICATION 2020-2030,($MILLION)
- TABLE 64. JAPAN EPIGENETICS MARKET BY END USER 2020-2030,($MILLION)
- TABLE 65. CHINA EPIGENETICS MARKET BY PRODUCT 2020-2030,($MILLION)
- TABLE 66. CHINA EPIGENETICS MARKET BY APPLICATION 2020-2030,($MILLION)
- TABLE 67. CHINA EPIGENETICS MARKET BY END USER 2020-2030,($MILLION)
- TABLE 68. AUSTRALIA EPIGENETICS MARKET BY PRODUCT 2020-2030,($MILLION)
- TABLE 69. AUSTRALIA EPIGENETICS MARKET BY APPLICATION 2020-2030,($MILLION)
- TABLE 70. AUSTRALIA EPIGENETICS MARKET BY END USER 2020-2030,($MILLION)
- TABLE 71. INDIA EPIGENETICS MARKET BY PRODUCT 2020-2030,($MILLION)
- TABLE 72. INDIA EPIGENETICS MARKET BY APPLICATION 2020-2030,($MILLION)
- TABLE 73. INDIA EPIGENETICS MARKET BY END USER 2020-2030,($MILLION)
- TABLE 74. SOUTH KOREA EPIGENETICS MARKET BY PRODUCT 2020-2030,($MILLION)
- TABLE 75. SOUTH KOREA EPIGENETICS MARKET BY APPLICATION 2020-2030,($MILLION)
- TABLE 76. SOUTH KOREA EPIGENETICS MARKET BY END USER 2020-2030,($MILLION)
- TABLE 77. REST OF ASIA-PACIFIC EPIGENETICS MARKET BY PRODUCT 2020-2030,($MILLION)
- TABLE 78. REST OF ASIA-PACIFIC EPIGENETICS MARKET BY APPLICATION 2020-2030,($MILLION)
- TABLE 79. REST OF ASIA-PACIFIC EPIGENETICS MARKET BY END USER 2020-2030,($MILLION)
- TABLE 80. LAMEA EPIGENETICS MARKET, BY PRODUCT, 2020-2030,($MILLION)
- TABLE 81. LAMEA EPIGENETICS MARKET, BY APPLICATION, 2020-2030,($MILLION)
- TABLE 82. LAMEA EPIGENETICS MARKET, BY END USER, 2020-2030,($MILLION)
- TABLE 83. LAMEA EPIGENETICS MARKET, BY COUNTRY, 2020-2030,($MILLION)
- TABLE 84. MIDDLE EAST AND AFRICA EPIGENETICS MARKET BY PRODUCT 2020-2030,($MILLION)
- TABLE 85. MIDDLE EAST AND AFRICA EPIGENETICS MARKET BY APPLICATION 2020-2030,($MILLION)
- TABLE 86. MIDDLE EAST AND AFRICA EPIGENETICS MARKET BY END USER 2020-2030,($MILLION)
- TABLE 87. LATIN AMERICA EPIGENETICS MARKET BY PRODUCT 2020-2030,($MILLION)
- TABLE 88. LATIN AMERICA EPIGENETICS MARKET BY APPLICATION 2020-2030,($MILLION)
- TABLE 89. LATIN AMERICA EPIGENETICS MARKET BY END USER 2020-2030,($MILLION)
- TABLE 90.ABCAM PLC.: COMPANY SNAPSHOT
- TABLE 91.ABCAM PLC.: OPERATING SEGMENTS
- TABLE 92.ABCAM PLC.: PRODUCT PORTFOLIO
- TABLE 93.ABCAM PLC.: NET SALES,
- TABLE 94.ABCAM PLC.: KEY STRATERGIES
- TABLE 95.ACTIVE MOTIF, INC.: COMPANY SNAPSHOT
- TABLE 96.ACTIVE MOTIF, INC.: OPERATING SEGMENTS
- TABLE 97.ACTIVE MOTIF, INC.: PRODUCT PORTFOLIO
- TABLE 98.ACTIVE MOTIF, INC.: NET SALES,
- TABLE 99.ACTIVE MOTIF, INC.: KEY STRATERGIES
- TABLE 100.AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT
- TABLE 101.AGILENT TECHNOLOGIES, INC.: OPERATING SEGMENTS
- TABLE 102.AGILENT TECHNOLOGIES, INC.: PRODUCT PORTFOLIO
- TABLE 103.AGILENT TECHNOLOGIES, INC.: NET SALES,
- TABLE 104.AGILENT TECHNOLOGIES, INC.: KEY STRATERGIES
- TABLE 105.HOLOGIC INC.: COMPANY SNAPSHOT
- TABLE 106.HOLOGIC INC.: OPERATING SEGMENTS
- TABLE 107.HOLOGIC INC.: PRODUCT PORTFOLIO
- TABLE 108.HOLOGIC INC.: NET SALES,
- TABLE 109.HOLOGIC INC.: KEY STRATERGIES
- TABLE 110.ILLUMINA INC.: COMPANY SNAPSHOT
- TABLE 111.ILLUMINA INC.: OPERATING SEGMENTS
- TABLE 112.ILLUMINA INC.: PRODUCT PORTFOLIO
- TABLE 113.ILLUMINA INC.: NET SALES,
- TABLE 114.ILLUMINA INC.: KEY STRATERGIES
- TABLE 115.MERCK MILLIPORE: COMPANY SNAPSHOT
- TABLE 116.MERCK MILLIPORE: OPERATING SEGMENTS
- TABLE 117.MERCK MILLIPORE: PRODUCT PORTFOLIO
- TABLE 118.MERCK MILLIPORE: NET SALES,
- TABLE 119.MERCK MILLIPORE: KEY STRATERGIES
- TABLE 120.PERKINELMER, INC.: COMPANY SNAPSHOT
- TABLE 121.PERKINELMER, INC.: OPERATING SEGMENTS
- TABLE 122.PERKINELMER, INC.: PRODUCT PORTFOLIO
- TABLE 123.PERKINELMER, INC.: NET SALES,
- TABLE 124.PERKINELMER, INC.: KEY STRATERGIES
- TABLE 125.QIAGEN N.V.: COMPANY SNAPSHOT
- TABLE 126.QIAGEN N.V.: OPERATING SEGMENTS
- TABLE 127.QIAGEN N.V.: PRODUCT PORTFOLIO
- TABLE 128.QIAGEN N.V.: NET SALES,
- TABLE 129.QIAGEN N.V.: KEY STRATERGIES
- TABLE 130.THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
- TABLE 131.THERMO FISHER SCIENTIFIC INC.: OPERATING SEGMENTS
- TABLE 132.THERMO FISHER SCIENTIFIC INC.: PRODUCT PORTFOLIO
- TABLE 133.THERMO FISHER SCIENTIFIC INC.: NET SALES,
- TABLE 134.THERMO FISHER SCIENTIFIC INC.: KEY STRATERGIES
- TABLE 135.ZYMO RESEARCH: COMPANY SNAPSHOT
- TABLE 136.ZYMO RESEARCH: OPERATING SEGMENTS
- TABLE 137.ZYMO RESEARCH: PRODUCT PORTFOLIO
- TABLE 138.ZYMO RESEARCH: NET SALES,
- TABLE 139.ZYMO RESEARCH: KEY STRATERGIES
- LIST OF FIGURES
- FIGURE 1.EPIGENETICS MARKET SEGMENTATION
- FIGURE 2.EPIGENETICS MARKET,2020-2030
- FIGURE 3.EPIGENETICS MARKET,2020-2030
- FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
- FIGURE 5.PORTER FIVE-1
- FIGURE 6.PORTER FIVE-2
- FIGURE 7.PORTER FIVE-3
- FIGURE 8.PORTER FIVE-4
- FIGURE 9.PORTER FIVE-5
- FIGURE 10.TOP PLAYER POSITIONING
- FIGURE 11.EPIGENETICS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
- FIGURE 11.EPIGENETICS MARKET,BY PRODUCT,2020(%)
- FIGURE 12.COMPARATIVE SHARE ANALYSIS OF KITS EPIGENETICS MARKET,2020-2030(%)
- FIGURE 13.COMPARATIVE SHARE ANALYSIS OF REAGENTS EPIGENETICS MARKET,2020-2030(%)
- FIGURE 14.COMPARATIVE SHARE ANALYSIS OF ENZYMES EPIGENETICS MARKET,2020-2030(%)
- FIGURE 15.COMPARATIVE SHARE ANALYSIS OF INSTRUMENTS EPIGENETICS MARKET,2020-2030(%)
- FIGURE 16.EPIGENETICS MARKET,BY APPLICATION,2020(%)
- FIGURE 17.COMPARATIVE SHARE ANALYSIS OF ONCOLOGY EPIGENETICS MARKET,2020-2030(%)
- FIGURE 18.COMPARATIVE SHARE ANALYSIS OF NON ONCOLOGY EPIGENETICS MARKET,2020-2030(%)
- FIGURE 19.EPIGENETICS MARKET,BY END USER,2020(%)
- FIGURE 20.COMPARATIVE SHARE ANALYSIS OF ACADEMIC AND RESEARCH INSTITUTES EPIGENETICS MARKET,2020-2030(%)
- FIGURE 21.COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES EPIGENETICS MARKET,2020-2030(%)
- FIGURE 22.COMPARATIVE SHARE ANALYSIS OF CONTRACT RESEARCH ORGANIZATIONS EPIGENETICS MARKET,2020-2030(%)
- FIGURE 23.EPIGENETICS MARKET BY REGION,2020
- FIGURE 24.U.S. EPIGENETICS MARKET,2020-2030($MILLION)
- FIGURE 25.CANADA EPIGENETICS MARKET,2020-2030($MILLION)
- FIGURE 26.MEXICO EPIGENETICS MARKET,2020-2030($MILLION)
- FIGURE 27.GERMANY EPIGENETICS MARKET,2020-2030($MILLION)
- FIGURE 28.FRANCE EPIGENETICS MARKET,2020-2030($MILLION)
- FIGURE 29.U.K. EPIGENETICS MARKET,2020-2030($MILLION)
- FIGURE 30.ITALY EPIGENETICS MARKET,2020-2030($MILLION)
- FIGURE 31.SPAIN EPIGENETICS MARKET,2020-2030($MILLION)
- FIGURE 32.REST OF EUROPE EPIGENETICS MARKET,2020-2030($MILLION)
- FIGURE 33.JAPAN EPIGENETICS MARKET,2020-2030($MILLION)
- FIGURE 34.CHINA EPIGENETICS MARKET,2020-2030($MILLION)
- FIGURE 35.AUSTRALIA EPIGENETICS MARKET,2020-2030($MILLION)
- FIGURE 36.INDIA EPIGENETICS MARKET,2020-2030($MILLION)
- FIGURE 37.SOUTH KOREA EPIGENETICS MARKET,2020-2030($MILLION)
- FIGURE 38.REST OF ASIA-PACIFIC EPIGENETICS MARKET,2020-2030($MILLION)
- FIGURE 39.MIDDLE EAST AND AFRICA EPIGENETICS MARKET,2020-2030($MILLION)
- FIGURE 40.LATIN AMERICA EPIGENETICS MARKET,2020-2030($MILLION)
- FIGURE 41. TOP WINNING STRATEGIES, BY YEAR
- FIGURE 42. TOP WINNING STRATEGIES, BY DEVELOPMENT
- FIGURE 43. TOP WINNING STRATEGIES, BY COMPANY
- FIGURE 44.PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 45.COMPETITIVE DASHBOARD
- FIGURE 46.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
- FIGURE 47.ABCAM PLC..: NET SALES ,($MILLION)
- FIGURE 48.ACTIVE MOTIF, INC..: NET SALES ,($MILLION)
- FIGURE 49.AGILENT TECHNOLOGIES, INC..: NET SALES ,($MILLION)
- FIGURE 50.HOLOGIC INC..: NET SALES ,($MILLION)
- FIGURE 51.ILLUMINA INC..: NET SALES ,($MILLION)
- FIGURE 52.MERCK MILLIPORE.: NET SALES ,($MILLION)
- FIGURE 53.PERKINELMER, INC..: NET SALES ,($MILLION)
- FIGURE 54.QIAGEN N.V..: NET SALES ,($MILLION)
- FIGURE 55.THERMO FISHER SCIENTIFIC INC..: NET SALES ,($MILLION)
- FIGURE 56.ZYMO RESEARCH.: NET SALES ,($MILLION)
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook